| 000 | 01920 a2200529 4500 | ||
|---|---|---|---|
| 005 | 20250516143945.0 | ||
| 264 | 0 | _c20131217 | |
| 008 | 201312s 0 0 eng d | ||
| 022 | _a1534-4681 | ||
| 024 | 7 |
_a10.1245/s10434-013-2960-3 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMagge, D | |
| 245 | 0 | 0 |
_aA phase I trial of isolated hepatic perfusion (IHP) using 5-FU and oxaliplatin in patients with unresectable isolated liver metastases from colorectal cancer. _h[electronic resource] |
| 260 |
_bAnnals of surgical oncology _cJul 2013 |
||
| 300 |
_a2180-7 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xadministration & dosage |
| 650 | 0 | 4 | _aArea Under Curve |
| 650 | 0 | 4 |
_aCarcinoembryonic Antigen _xblood |
| 650 | 0 | 4 |
_aChemotherapy, Cancer, Regional Perfusion _xadverse effects |
| 650 | 0 | 4 |
_aColorectal Neoplasms _xblood |
| 650 | 0 | 4 | _aDisease-Free Survival |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aFluorouracil _xadministration & dosage |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aKaplan-Meier Estimate |
| 650 | 0 | 4 |
_aLiver Neoplasms _xblood |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMaximum Tolerated Dose |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aOrganoplatinum Compounds _xadministration & dosage |
| 650 | 0 | 4 | _aOxaliplatin |
| 700 | 1 | _aZureikat, A H | |
| 700 | 1 | _aBartlett, D L | |
| 700 | 1 | _aHoltzman, M P | |
| 700 | 1 | _aChoudry, H A | |
| 700 | 1 | _aBeumer, J H | |
| 700 | 1 | _aPingpank, J F | |
| 700 | 1 | _aHolleran, J L | |
| 700 | 1 | _aStrychor, S | |
| 700 | 1 | _aCunningham, D E | |
| 700 | 1 | _aJones, H L | |
| 700 | 1 | _aZeh, H J | |
| 773 | 0 |
_tAnnals of surgical oncology _gvol. 20 _gno. 7 _gp. 2180-7 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1245/s10434-013-2960-3 _zAvailable from publisher's website |
| 999 |
_c22659713 _d22659713 |
||